Literature DB >> 30993712

NK cells: An attractive candidate for cancer therapy.

Behnaz Valipour1,2, Kobra Velaei2, Ali Abedelahi2, Mohammad Karimipour2, Masoud Darabi3, Hojjatollah Nozad Charoudeh1.   

Abstract

Natural killer (NK) cells have significant capability in tumor immune-surveillance. The ability of lyse transformed cells immediately in an antigen-independent manner make them an attractive candidate for cancer cell therapy. Despite employment of NK cells in cancer immunotherapy, clinical trials are faced with serious limitations such as trouble with the penetration of NK cells in tumor sites, limited in vivo persistence, and tumor microenvironment interference. Taken together, the NK-cell cancer therapy is still infant scenario that has a long way to be translated in clinic. Current article first reviews characteristic features of NK lymphocytes. Then, it discusses about important disruptive barriers and motivator in the developmental stages of NK cells like as tumor microenvironment. Finally, some revolutionary approaches are highlighted utilizing of NK cells in cancer therapy.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  ADCC; cell therapy; natural killer cells; tumor microenvironment

Mesh:

Year:  2019        PMID: 30993712     DOI: 10.1002/jcp.28657

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  16 in total

1.  Fatty acids promote the expansion of NK-92 cells in vitro by improving energy metabolism.

Authors:  Zhepei Xie; Yan Fu; Wen-Song Tan; Haibo Cai
Journal:  Appl Microbiol Biotechnol       Date:  2021-05-15       Impact factor: 4.813

Review 2.  Advances in plant-derived natural products for antitumor immunotherapy.

Authors:  Yi Yang; Qinying Liu; Xianai Shi; Qiuhong Zheng; Li Chen; Yang Sun
Journal:  Arch Pharm Res       Date:  2021-11-09       Impact factor: 4.946

Review 3.  The role of the natural killer (NK) cell modulation in breast cancer incidence and progress.

Authors:  Ehsan Razeghian; Mahdis Chahar Kameh; Sepehr Shafiee; Farima Khalafi; Fehimeh Jafari; Mohammadali Asghari; Kiarash Kazemi; Saba Ilkhani; Siavash Shariatzadeh; Arvin Haj-Mirzaian
Journal:  Mol Biol Rep       Date:  2022-08-25       Impact factor: 2.742

4.  m6A regulator-mediated methylation modification highlights immune infiltration patterns for predicting risk in hepatocellular carcinoma.

Authors:  Dongkai Zhou; Yizhi Wang; Wei Wei; Wei Zhou; Jin Gu; Yang Kong; Qifan Yang; Yingsheng Wu
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-16       Impact factor: 4.322

5.  N6-methyladenosine methylation modification patterns reveal immune profiling in pancreatic adenocarcinoma.

Authors:  Hao Xu; Lu Yin; Qianhui Xu; Jingjing Xiang; Rujun Xu
Journal:  Cancer Cell Int       Date:  2022-05-23       Impact factor: 6.429

Review 6.  Effect of P2X purinergic receptors in tumor progression and as a potential target for anti-tumor therapy.

Authors:  Wen-Jun Zhang
Journal:  Purinergic Signal       Date:  2021-01-09       Impact factor: 3.765

Review 7.  Interactions of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) with the Immune System: Implications for Inflammation and Cancer.

Authors:  Katharina Beyer; Ann-Kathrin Baukloh; Ani Stoyanova; Carsten Kamphues; Arne Sattler; Katja Kotsch
Journal:  Cancers (Basel)       Date:  2019-08-13       Impact factor: 6.639

Review 8.  CARs: Beyond T Cells and T Cell-Derived Signaling Domains.

Authors:  Nico M Sievers; Jan Dörrie; Niels Schaft
Journal:  Int J Mol Sci       Date:  2020-05-15       Impact factor: 5.923

9.  Prognostic value of peripheral blood natural killer cells in colorectal cancer.

Authors:  Yan-Ping Tang; Ming-Zhi Xie; Ke-Zhi Li; Ji-Lin Li; Zheng-Min Cai; Bang-Li Hu
Journal:  BMC Gastroenterol       Date:  2020-02-07       Impact factor: 3.067

Review 10.  Reversal of the immunosuppressive tumor microenvironment by nanoparticle-based activation of immune-associated cells.

Authors:  Fei-Long Qi; Mei-Fang Wang; Bo-Zhao Li; Ze-Fang Lu; Guang-Jun Nie; Su-Ping Li
Journal:  Acta Pharmacol Sin       Date:  2020-05-28       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.